Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
NCT01285570 is registered in ClinicalTrials.gov with Tranzyme, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
- Lead sponsor
- Tranzyme, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- January 31, 2012
- Enrollment
- 332 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.
gastrointestinal dysmotility